Quality Assurance Issues and Interpretation of Assays

Seminars in Hematology

Volumn 44, Issue 2, 2007, Pages 114-125

  Mackie, Ian ^a   Cooper, Peter ^b   Kitchen, Steve ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CONTRACEPTIVE AGENT; HEPARIN; PROTEIN C; PROTEIN S;

ARTICLE; ASSAY; BLOOD CLOTTING; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LABORATORY TEST; MEASUREMENT; PRIORITY JOURNAL; QUALITY CONTROL; THROMBOEMBOLISM; THROMBOPHILIA; VALIDATION PROCESS;

BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; HUMANS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; THROMBOPHILIA;

EID: 34047261848     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.01.001     Document Type: Article

References (67)

1. BCSH (British Committee for Standards in Haematology) Haemostasis and Thrombosis Task Force. Guideline: Investigation and management of heritable thrombophilia. Br J Haematol 114 (2001) 512-528
2. BCSH (British Committee for Standards in Haematology) Haemostasis and Thrombosis Task Force. Guideline: The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol 119 (2002) 295-309
3. Favaloro E.J., Bonnar R., Sioufi J., Wheeler M., Low J., Aboud M., et al. Multilaboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Semin Thromb Hemost 31 (2005) 49-58
4. Meijer P., Haverkate F., and Kluft K. Performance goals for the laboratory testing of antithrombin, protein C and protein S. Thromb Haemost 96 (2006) 584-589
5. Jennings I., Kitchen S., Woods T.A.L., and Preston F.E. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 31 (2005) 66-72
6. Kauffmann R.H., Veltkamp J.J., Van Tilberg N.H., and Van Es L.A. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 65 (1978) 607-613
7. White B., and Berry D. Review-Acquired antithrombin deficiency in sepsis. Br J Haematol 112 (2001) 26-31
8. Ceriello A., Dello Russo P., Zuccotti C., Florio A., Nazzaro S., et al. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation-A preliminary report. Thromb Haemost 50 (1983) 633-634
9. The Antithrombin Mutation Database. (http://www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin/)
10. Tran Tri H., and Duckert F. Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res 40 (1985) 571-576
11. Demers C., Henderson P., Blajchman M.A., Wells M.J., Mitchell L., Johnston M., et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 69 (1993) 231-235
12. Beauchamp N.J., Pike R.N., Daly M., Butler M., Makris M., Dafforn T.R., et al. Antithrombin Wibble and Wobble (T85M/K): Archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 92 (1998) 2696-2706
13. Perry D.J., Daly M.E., Tait R.C., Walker I.D., Brown K., Beauchamp N.J., et al. Antithrombin Cambridge II (Ala384Ser): Clinical, functional and haplotype analysis of 18 families. Thromb Haemost 79 (1998) 249-253
14. Ungerstedt J.S., Schulman S., Egberg N., Antovic J., and Blomback M. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood 99 (1992) 2271-2272
15. Harper P.L., Luddington R.J., Daly M., Bruce D., Williamson D., Edgar P.F., et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 77 (1991) 360-364
16. Dolan G., Neal K., Cooper P., Brown P., and Preston F.E. Protein C, antithrombin III and plasminogen: Effect of age, sex and blood group. Br J Haematol 86 (1994) 798-803
17. Walker I.D. Reference ranges in haemostasis. In: Rowan R.M., van Assendelft O.W., and Preston F.E. (Eds). Advanced Laboratory Methods in Haematology (2002), Arnold, London, UK 338-351
18. Dahlback B., Carlsson M., and Svenson P.J. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1008
19. Rosen S., Johansson K., Lindberg K., and Dahlback B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 72 (1994) 255-260
20. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
21. Beauchamp N.J., Daly M.E., Cooper P.C., Preston F.E., and Peake I.R. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 334 (1994) 694-695
22. De Visser M.C.H., Rosendaal F.R., and Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
23. Tosetto A., and Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 73 (1995) 732-733
24. De Ronde H., and Bertina R.M. Careful selection of sample dilution and factor V deficient plasma makes the modified APC resistance test highly specific for the factor V Leiden mutation. Blood Coagul Fibrinolysis 10 (1999) 7-17
25. Gardiner C., Cooper P.C., Makris M., Mackie I.J., Malia R.G., and Machin S.J. An evaluation of screening tests for defects in the protein C pathway: Commercial kits lack sensitivity and specificity. Blood Coagul Fibrinolysis 13 (2002) 155-163
26. Toulon P., Halbmeyer W.M., Hafner G., Schmitt Y., Randgard B., Odpadlik M., et al. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation. Blood Coagul Fibrinolysis 11 (2000) 447-454
27. Quincampoix J.C., Legarff M., Rittling C., Andiva S., and Toulon P. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation. Blood Coagul Fibrinolysis 12 (2001) 569-576
28. Guasch J.F., Lensen R.P.M., and Beryina R.M. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost 77 (1997) 252-257
29. Dargaud Y., Trzeciak M.C., Meunier S., Angei C., Pellechia D., Negrier C., et al. Two novel factor V null mutations associated with activated protein C resistance/genotype discrepancy. Br J Haematol 123 (2003) 342-345
30. Cooper P.C., Cooper S.M., Smith J.M., Kitchen S., and Makris M. Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G2010A genotypes from blood samples without the need for DNA extraction. Blood Coagul Fibrinolysis 14 (2003) 499-503
31. Patnaik M., Dlott J.S., Fontaine R.N., Subbiah M.T., Hessner M.J., Joyner K.A., et al. Detection of genomic polymorphisms associated with venous thrombosis using the Invader biplex assay. J Mol Diagn 6 (2004) 137-143
32. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363-365
33. Kwok S., and Higuchi R. Avoiding false positives with PCR. Nature 339 (1984) 237-238
34. Preston F.E., Kitchen S., Jennings I., and Woods T.A. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost 82 (1999) 1556-1557
35. Tripodi A., Peyvandi F., Chantarangkul V., Menegatti M., and Mannucci P.M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-A cause for concern. Thromb Haemost 88 (2002) 690-691
36. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
37. Itakura H., Telen M.J., Hoppe C.C., White D.A.E., and Zehnder J.L. Characterization of a novel prothrombin variant, prothrombin C20209T, as a modifier of thrombotic risk among African-Americans. Thromb Haemost 3 (2005) 2357-2359
38. Wylenzek M., Geison C., Stapenhorst L., Wielckens K., and Klingler K.R. A novel point mutation in the 3′ region of the prothrombin gene at position 20221 in a Lebanese/Syrian family. Thromb Haemost 85 (2001) 943-944
39. Miletich J., Sherman L., and Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317 (1987) 991-996
40. Koeleman B.P., Reitsma P.H., Allaart C.F., and Bertina R.M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84 (1994) 1031-1035
41. Tait R.C., Walker I.D., Islam S.I.A., Mitchell R., Conkie J.A., Macall F., et al. Age related changes in protein C activity in healthy adult males. Thromb Haemost 65 (1991) 326-327
42. Guglielmone H.A., and Vides M.A. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemost 67 (1992) 46-49
43. Pabinger I., Allaart C.F., Hermans J., Briet E., Bertina R.M., and Protein C transmitter group. Hereditary protein C deficiency: Laboratory values in transmitters and guidelines for the diagnosis procedure. Report on a study of the SSC subcommittee on protein C and protein S. Thromb Haemost 68 (1992) 470-474
44. D'Angelo S.V., Gilardoni F., and D'Angelo A. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. Thromb Haemost 62 (1989) 861-867
45. Jennings I., Kitchen S., Cooper P.C., Rimmer J.E., Woods T.A.L., and Preston F.E. Further evidence that activated protein C resistance affects protein C coagulant activity assays. Thromb Haemost 83 (2000) 171-172
46. Marlar R.A., Adcock D.M., and Madden R.M. Hereditary dysfunctional protein C molecules (type II): Assay characterization and proposed classification. Thromb Haemost 63 (1990) 375-379
47. Bovill E.G., Tomczak J.A., Grant B., Bhushan F., Pillemer E., Rainville I.R., et al. Protein C Vermont: Symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 79 (1992) 1456-1465
48. Mackie I.J., Gallimore M., and Machin S.J. Contact factor proteases and the complexes formed with alpha 2-macroglobulin can interfere in protein C assays by cleaving amidolytic substrates. Blood Coagul Fibrinolysis 3 (1992) 589-595
49. Mikami S., and Tuddenham E.G.D. Studies on immunological assay of vitamin-K dependant factors II. Comparison of four immunoassay methods with functional activity of protein C in human plasma. Br J Haematol 62 (1986) 183-193
50. Faioni E.M., Hermida J., Rovida E., Razzari C., Asti D., Zeinali S., et al. Type II protein C deficiency: Identification and molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity. Br J Haematol 108 (2000) 265-271
51. Koeleman B.P., van Rumpt D., Hamulyak K., Reitsma P.H., and Bertina R.M. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families. Thromb Haemost 74 (1995) 580-583
52. Dykes A.C., Walker I.D., McMahon A.D., Islam S.I., and Tait R.C. A study of protein S antigen levels in 3788 healthy volunteers: Influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 113 (2001) 636-641
53. Makris M., Leach M., Beauchamp N.J., Daly M.E., Cooper P.C., Hampton K.K., et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 95 (2000) 1935-1941
54. Woodhams B.J. The simultaneous measurement of total and free protein S by ELISA. Thromb Res 50 (1988) 213-220
55. Faioni E.M., Franchi F., Asti D., Sacchi E., Bernadi F., and Mannucci P.M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 70 (1993) 1067-1071
56. Cooper P.C., Hampton K.K., Makris M., Abuzenadah A., Paul B., and Preston F.E. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 88 (1994) 201-203
57. Jennings I., Kitchen S., Woods T.A.L., and Preston F.E. Diagnostic errors in thrombophilia screening: Evidence from the UK NEQAS. Thromb Haemost Suppl 276 (1999) (suppl 1, abstr 867)
58. Makris M. Hyperhomocysteinaemia and thrombosis. Clin Lab Haem 22 (2000) 133-143
59. Mezzano D., Munoz X., Martinez C., Cuevas A., Panes O., Aranda E., et al. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 81 (1999) 913-917
60. Palmer-Toy D.E., Szczepiorkowski Z.M., Shih V., and van Cott E.M. Comparability of the Abbott Imx homocysteine assay with citrate-anticoagulated plasma and stability of homocysteine in citrated whole blood. Clin Chem 47 (2001) 1704-1707
61. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott Imx analyzer. Clin Chem 45 (1999) 569-571
62. Rasmussen K., Moller J., and Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Clin Chem 45 (1999) 1850-1855
63. Tripodi A., Chantarangkul V., Lombardi R., Lecchi A., Mannucci P.M., and Cattaneo M. Multicenter study of homocysteine measurement-Performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost 85 (2001) 291-295
64. Jennings I., Kitchen S., Smith J., Woods T.A.L., and Preston F.E. Between-centre agreement in homocysteine assays: Experience from the UK NEQAS proficiency testing scheme. Thromb Haemost 87 (2002) 921-922
65. Tripodi A., and Mannucci P.M. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 42 (1996) 664-669
66. Tripodi A., Chantarangkul V., Bottasso B., and Mannucci P.M. Poor comparability of Prothrombin fragment 1+ 2 values measured by 2 different commercial ELISA methods: Influence of different anticoagulants and standards. Thromb Haemost 71 (1994) 605-608
67. Hursting M.J., Slaughter T.F., Stead A.G., Szewczyk K.M., Witt D.J., and Greenberg C.S. Standardisation of prothrombin fragment 1.2 measurement: Effects of pre-analytical variables and calibrator selection. Arch Pathol Lab Med 122 (1998) 31-36